PAT and Real Time Quality on December 05-07, 2023 in Boston, United States

With drug developers and manufacturers facing closer scrutiny on product quality than ever before, it's time to make the most of evolving process analytical technology to design robust and cost-effective control strategies and understand more about your biopharmaceutical products.

The likes of Bristol Myers Squibb, BMS, Vertex, Moderna, Sanofi and Novo Nordisk and more are uniting this December at the 2nd PAT and Real Time Quality Summit to revolutionize real-time quality strategies across a wide range of novel modality applications, and share advances in machine learning that are making real-time control and diversion a reality.

Whilst the sector still battles with justifying investment and integration, the summit demonstrates tangible return on investment for process analytical technology in drug development and GMP environments, through increased yield, inline and online monitoring, predictive modelling, and accelerated speed to market.

Join 60+ PAT experts, including process development, analytical development, MSAT directors, and chemometricians; at the one and only end-to-end playbook for the successful advancement, integration, and adoption of process analytical technology in highly regulated pharmaceutical environments.

URLs:

Tickets: https://go.evvnt.com/1904125-2?pid=10008

Brochure: https://go.evvnt.com/1904125-3?pid=10008

Time: 9:00 AM - 5:30 PM

Prices:

Drug Developer Pricing - Conference Only: USD 2999.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,

Drug Developer Pricing - Conference + 2 workshops: USD 4297.00,

Academic Pricing - Conference Only: USD 2599.00,

Academic Pricing - Conference + 1 Workshop: USD 3148.00,

Academic Pricing - Conference + 2 workshops: USD 3697.00,

Solution Provider Pricing - Conference Only: USD 3799.00,

Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,

Solution Provider Pricing - Conference + 2 workshops: USD 5297.00

Speakers: Marina Hincapie, Head of Process Analytical Technology Development, Sanof, Karin Balss, Scientific Fellow, MSAT, Janssen Pharmaceuticals, Marianne Langston, Associate Scientific, Fellow Takeda, Mathieu Bibian, Associate Director, Analytical R AND D, GSK, Wei-Chiang Chen, Associate Director - BioProcess Analytics - Genomic Medicine Unit, Sanof, Elliott Schmitt, Principal Engineer - Process Analytical Technology, Moderna, Qinglin Su, Principal Scientist - Process Systems, Engineering Vertex, Yuanyuan Cui, Principal Engineer, MSAT, Sanof, Andreas KunovKruse, Senior Scientist, Analytical Technology in Manufacturing Development IFP, Novo Nordisk, Mohammad Rashedi, Data Scientist, Operations Advanced Analytics (OAA), Amgen, Sarah Rajani, Scientist, Process Analytical Technologies Bristol Myers, Squibb, Ben Espen, Principal Quality Engineer Lead, Avobis Bio, Dennis Ungan, Principal Scientist, Novartis, Ricardo Heredia, Scientist, Digital Bioprocessing, Sanof, Dariusz Domagala, Project Manager, Process Analytical Technology, Novo Nordisk, Bharat Mankani, Process Analytical Technology Group Lead, PPG Industries, Alexander Santos, Regulatory Scientist Voisin Consulting, Life Sciences, Sean Hart, Chief Executive Officer and Chief Scientific Officer, LumaCyte, Stacy Shollenberger, Senior Marketing Manager, Process Analytical Technology, MilliporeSigma, Bruce Greenwald, DeltaV Platform Business Development Manager, Emerson Automation Solutions